Sagimet Biosciences Inc. Series A (SGMT) Dividend History

Company News

• Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Sagimet Biosciences, a clinical-stage biopharmaceutical company, announced that it will present at a virtual conference and granted stock options to new employees as inducement grants.

  GlobeNewswire Inc.
• Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

  Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance for accelerated approval in MASH

  GlobeNewswire Inc.
• Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday

  Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Stifel cut the price target for Spire Global, Inc. (NYSE:SPIR) from $24 to $20. Stifel analyst Erik Rasmussen maintained a Buy rating. Spire Global shares fell 6.8% to close at $11.34 on Wednesday. See how other analysts view this stock. Oppenheimer boosted the price target for Analog Devices, Inc. (NASDAQ:ADI) from $215 to $245. Oppenheimer analyst Rick Schafer maintained an Outperform rating. Analog Devices shares rose 1.8% to close at $215.75 on Wednesday. See how other analysts view this stock. Goldman Sachs cut Sagimet Biosciences Inc.. (NASDAQ:SGMT) price target from $27 to $23. Goldman Sachs analyst Andrea Tan maintained a Buy rating. Sagimet Biosciences shares rose 5.5% to close ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: ACN ADI FATE MNDY OXY POR SPIR ZBRA
• Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

  Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH

  GlobeNewswire Inc.
• Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

  SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024.

  GlobeNewswire Inc.